Key clinical point: Lurasidone is associated with a favorable cardiometabolic profile than olanzapine in patients with schizophrenia.
Major finding: At 6 weeks, levels of low-density lipoprotein, very low-density lipoprotein, total cholesterol, and triglycerides significantly increased in the olanzapine group and decreased in the lurasidone group, with significant differences between groups (P less than .001 for all). Lurasidone group also had a significantly lower atherogenic, coronary, and cardiovascular risk indices vs. olanzapine (P less than .001 for all).
Study details: An open-label, parallel design, active-controlled clinical trial of 101 patients randomly assigned (1:1) to receive lurasidone or olanzapine.
Disclosures: The study received funding from the All India Institute of Medical Sciences, Bhubaneswar, India. The authors reported no conflicts of interest.
Jena M et al. Psychopharmacology (Berl). 2020 Aug 1. doi: 10.1007/s00213-020-05628-3.